Having wrapped up the first phase of reverse circulation (RC) drilling, Pantoro Ltd has fielded positive gold results at the Hinemoa Fault on the Polar Bear peninsula, a key target within its Norseman Gold Project in Western Australia.
Diversified Energy Company PLC (LSE:DEC, NYSE:DEC) has struck a new partnership with FuelCell Energy and TESIAC to develop 360 megawatts of power generation capacity for data centres in Virginia, West Virginia, and Kentucky.
The collaboration will use natural gas and coal mine methane to provide off-grid power, reducing dependence on traditional grid infrastructure in the development of data centres.
North Bay Resources Inc. (OTC:NBRI) reported high-grade copper, silver, and vanadium mineralization from its February 2025 exploration program at the Copper Island project in British Columbia.
Rock sampling from eight outcrops at the Pomeroy 1-3, Beaver, and Copper Bell zones returned assay values as high as 5.69% copper, 1 ounce per ton silver, and 0.22% vanadium.
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug Administration (FDA) for urcosimod, for the treatment of neuropathic corneal pain (NCP).
The FDA's Fast Track designation is intended to accelerate the development and review of treatments for serious conditions with unmet medical needs, potentially expediting urcosimod's path to market if it is granted.
HIVE Digital Technologies (TSX-V:HIVE, NASDAQ:HIVE) reported mining 89 Bitcoin (BTC) in February, bringing its total BTC holdings to 2,620, valued at $220 million as of February 28.
The company maintained an average mining capacity of 5.6 exahash per second (EH/s), reaching a peak BTC-only hashrate of 6.2 EH/s.
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) shares climbed 5% in early trading after securing a major deal to expand its Xenon MRI technology into pharmaceutical research.
A top global pharmaceutical company has selected Polarean’s imaging services for a multi-centre clinical trial, which will evaluate an investigational lung treatment.
Shore Capital has initiated coverage on hVIVO PLC (AIM:HVO) with a bullish outlook, setting a 'fair value' target of 35p per share — more than double its current trading price of 17.22p.
The firm believes hVIVO, a specialist in human challenge trials (HCTs), is well-positioned for strong growth as pharmaceutical companies ramp up investment in infectious and respiratory disease research.
Critical Mineral Resources PLC (LSE:CMRS) has secured a £2.5 million investment from Gilini Holdings Ltd to fund its activities in Morocco.
Proceeds will aid the company in making new acquisitions and support its commodity trading activities.
Shares in Roquefort Therapeutics PLC (LSE:ROQ) soared 71% in the first hour of trading after the biotech firm agreed to sell its subsidiary, Oncogeni, to UAE-based Nations Trust Holding for up to $12 million (£9.3 million).
The deal includes an upfront payment and milestone-based payouts, though both sides still need to finalise a binding agreement within the next 60 days.
Empire Metals Ltd (AIM:EEE) told investors it has produced a high-purity titanium dioxide (TiO₂) product from its Pitfield Project in Western Australia.
Preliminary testwork delivered a 91.6% TiO₂ assay, with no deleterious impurities detected, the company said.
Roquefort Therapeutics PLC (LSE:ROQ) has agreed to sell its subsidiary, Oncogeni, to UAE-based Nations Trust Holding for up to $12 million (£9.3 million).
The deal, consisting of an upfront sum and milestone payments, is still at the term sheet stage, meaning both sides have agreed on the key terms but need to finalise a binding agreement within the next 60 days.
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has successfully expanded its new imaging service model by securing a deal to expand its Xenon MRI imaging platform into pharmaceutical research, marking a big step forward for the company.
An unnamed leading global pharmaceutical firm has chosen Polarean’s technology for a multicentre clinical trial, testing an investigational lung treatment. The trial will use Xenon MRI to assess how the new therapy affects lung function, providing detailed insights into ventilation and gas exchange.
Resolution Minerals Ltd has turned its attention to antimony with gold and copper upside after entering into a Binding Agreement to acquire three highly prospective exploration projects in New South Wales and Queensland, covering a total of approximately 194 square kilometres.
Resolution’s binding term sheet is with Devil Prospecting Pty Ltd and 1205 Pty Ltd to acquire 100% of their issued share capital and exploration licences EL 9730, EL 9719, EL 9720, and EPM 29111.